Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gianantonio Rosti

Showing results (51-60 of 153) with videos related to

Pageof 16
Sort By:
Cancer|April 21, 2012
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapyMarzia Defina, Micaela Ippoliti, Alessandro Gozzetti, et al.
Leukemia Research|March 14, 2024
Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND studyB Douglas Smith, Tim H Brümmendorf, Gail J Roboz, et al.
International Journal of Hematology|March 2, 2022
Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysisNaoto Takahashi, Jorge E Cortes, Emiko Sakaida, et al.
Oncotarget|May 19, 2018
Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patientsMaria Rosaria Ricciardi, Valentina Salvestrini, Roberto Licchetta, et al.
Journal of Hematology & Oncology|December 6, 2019
Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paperSimona Soverini, Elisabetta Abruzzese, Monica Bocchia, et al.
Journal of Cellular Biochemistry|April 13, 2017
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation AdvantageManuela Mancini, Fausto Castagnetti, Simona Soverini, et al.
Blood|April 7, 2011
Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinibJorge E Cortes, Andreas Hochhaus, Philipp D le Coutre, et al.
Annals of Hematology|October 1, 2016
Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinionMassimo Breccia, Patrizia Pregno, Paolo Spallarossa, et al.
Blood|May 13, 2011
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNetSimona Soverini, Andreas Hochhaus, Franck E Nicolini, et al.
Blood|March 19, 2013
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phaseAndreas Hochhaus, Giuseppe Saglio, Richard A Larson, et al.
Pageof 16

Showing results (51-60 of 153) with videos related to

Sort By:
Pageof 16
Cancer|April 21, 2012
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapyMarzia Defina, Micaela Ippoliti, Alessandro Gozzetti, et al.
Leukemia Research|March 14, 2024
Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND studyB Douglas Smith, Tim H Brümmendorf, Gail J Roboz, et al.
International Journal of Hematology|March 2, 2022
Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysisNaoto Takahashi, Jorge E Cortes, Emiko Sakaida, et al.
Oncotarget|May 19, 2018
Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patientsMaria Rosaria Ricciardi, Valentina Salvestrini, Roberto Licchetta, et al.
Journal of Hematology & Oncology|December 6, 2019
Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paperSimona Soverini, Elisabetta Abruzzese, Monica Bocchia, et al.
Journal of Cellular Biochemistry|April 13, 2017
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation AdvantageManuela Mancini, Fausto Castagnetti, Simona Soverini, et al.
Blood|April 7, 2011
Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinibJorge E Cortes, Andreas Hochhaus, Philipp D le Coutre, et al.
Annals of Hematology|October 1, 2016
Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinionMassimo Breccia, Patrizia Pregno, Paolo Spallarossa, et al.
Blood|May 13, 2011
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNetSimona Soverini, Andreas Hochhaus, Franck E Nicolini, et al.
Blood|March 19, 2013
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phaseAndreas Hochhaus, Giuseppe Saglio, Richard A Larson, et al.
Pageof 16